News

May 18, 2012 -- St. Jude Medical Inc., a global medical device company, announced that preliminary data demonstrated the company’s EnligHTN renal denervation system was safe and effective for the...

May 15, 2012 – St. Jude Medical Inc., a global medical device company, announced CE mark approval and launch of its EnligHTN renal denervation system during EuroPCR. Renal denervation is a...

May 9, 2012 — Sound Interventions Inc. announced the successful completion of the company's first-in-human clinical trial to treat resistant hypertension, SOUND-ITV.

May 4, 2012 - Medtronic Inc. announced six-month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity renal...

May 2, 2012 — Vessix Vascular Inc. announced this week that it has received CE mark approval for its V2 Renal Denervation System for the treatment of hypertension. Renal denervation is a...

ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked Paradise (percutaneous renal denervation system) ultrasound platform, which is...

April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment...

Internet-based telemedicine systems appear to lead to more appropriate and effective pharmacotherapy, better blood pressure control and an overall reduction in cardiovascular risk compared to...

March 13, 2012 — Asahi Kasei Corp.  and Zoll Medical Corp. jointly announced that Asahi Kasei will acquire Zoll for approximately $2.21 billion.

February 29, 2012 — Vessix Vascular Inc. announced initial patient treatments in the international multi-center Reduce-HTN renal denervation clinical study for uncontrolled hypertension.

PARADISE

February 20, 2012 — ReCor Medical announced that its Paradise percutaneous ultrasound renal denervation system for achieving rhas received the CE mark. Paradise is designed to treat patients with...

February 15, 2012 — Vessix Vascular Inc., developer of a novel percutaneous radiofrequency (RF) balloon catheter technology, announced that it will make its first detailed public presentation of...

February 15, 2012 — Medtronic Inc. announced the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s Symplicity renal denervation system across...

November 21, 2011 – Royal Philips Electronics introduced Philips HeartStart FR3 automated external defibrillator (AED) in the United States for professional responders who treat victims of sudden...

November 16, 2011 – Johnson & Johnson Pharmaceutical Research & Development announced that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite...

November 15, 2011 – A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting...

October 26, 2011 — Medtronic Inc. announced the start of SYMPLICITY HTN-3, the company’s United States clinical trial of the Symplicity Renal Denervation System for treatment-resistant...

September 13, 2011 – A new study finds that infections following cardiac device implantations or replacement result in extremely high costs, both financially and in terms of patient mortality,...

September 12, 2011 — Cardiovascular market research firm Zacks Equity Research released a new report discussing high growth areas in medical devices, including Medtronic Inc., Boston Scientific...

August 31, 2011 — A recent study revealed more than 1,000 cardiac arrest deaths over 15 years are connected to the failure of automated external defibrillators (AEDs); battery failure accounted...